Preliminary efficacy and safety of a dose-intensified C5VD regimen in 24 children with locally advanced hepatoblastoma.
10.7499/j.issn.1008-8830.2502113
- Author:
Jia-Xin PENG
1
;
Can HUANG
;
An-An ZHANG
1
;
Ya-Li HAN
1
;
Hai-Shan RUAN
1
;
Xiao-Xia WANG
;
Min XU
;
Yuan XIN
;
Li-Ting YU
;
Zhi-Bao LYU
;
Sha-Yi JIANG
;
Yi-Jin GAO
1
Author Information
1. Department of Oncology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China.
- Publication Type:Journal Article
- Keywords:
C5VD regimen;
Child;
Efficacy;
Hepatoblastoma;
Ototoxicity;
Safety
- MeSH:
Humans;
Hepatoblastoma/pathology*;
Male;
Female;
Infant;
Liver Neoplasms/pathology*;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use*;
Child, Preschool;
Prospective Studies;
Doxorubicin/adverse effects*;
Child;
Cisplatin/adverse effects*;
Vincristine/adverse effects*;
Fluorouracil/adverse effects*
- From:
Chinese Journal of Contemporary Pediatrics
2025;27(10):1247-1252
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVES:To assess the preliminary efficacy and safety of a dose-intensified C5VD regimen (cisplatin, 5-fluorouracil, vincristine, and doxorubicin) in children with locally advanced hepatoblastoma.
METHODS:This prospective study enrolled 24 children with newly diagnosed, locally advanced hepatoblastoma who received the dose-intensified C5VD regimen at Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, and Shanghai Children's Hospital between January 2020 and December 2023. Clinical characteristics, treatment outcomes, and chemotherapy-related toxicities were analyzed.
RESULTS:Of the 24 patients, 13 were male and 11 were female, with a median age at diagnosis of 18.7 months (range: 3.5-79.4 months). All patients achieved complete macroscopic resection of hepatic lesions without liver transplantation. Serum alpha-fetoprotein levels decreased significantly after two chemotherapy cycles. During a median follow-up of 38.4 months (range: 15.8-50.7 months), all patients maintained continuous complete remission, with 3-year event-free survival and overall survival rates of 100%. Across 144 chemotherapy cycles, the incidence rates of grade 3-4 neutropenia, thrombocytopenia, and infections were 97%, 77%, and 71%, respectively; no treatment-related deaths occurred. Notably, 5 patients (21%) developed Brock grade ≥3 hearing loss, of whom 1 required a hearing aid.
CONCLUSIONS:The dose-intensified C5VD regimen demonstrates significant efficacy with an overall favorable safety profile in the treatment of newly diagnosed, locally advanced pediatric hepatoblastoma. Grade 3-4 myelosuppression and infection are the predominant toxicities. However, high‑dose cisplatin-induced ototoxicity remains a concern, highlighting the need for improved otoprotective strategies.
